Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Operating Leases: 2019-2024

Historic Operating Leases for Whitehawk Therapeutics (WHWK) over the last 5 years, with Dec 2024 value amounting to $565,000.

  • Whitehawk Therapeutics' Operating Leases fell 55.41% to $565,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $565,000, marking a year-over-year decrease of 55.41%. This contributed to the annual value of $565,000 for FY2024, which is 55.41% down from last year.
  • As of FY2024, Whitehawk Therapeutics' Operating Leases stood at $565,000, which was down 55.41% from $1.3 million recorded in FY2023.
  • Over the past 5 years, Whitehawk Therapeutics' Operating Leases peaked at $1.7 million during FY2022, and registered a low of $565,000 during FY2024.
  • Over the past 3 years, Whitehawk Therapeutics' median Operating Leases value was $1.3 million (recorded in 2023), while the average stood at $1.2 million.
  • In the last 5 years, Whitehawk Therapeutics' Operating Leases surged by 174.55% in 2022 and then tumbled by 55.41% in 2024.
  • Over the past 4 years, Whitehawk Therapeutics' Operating Leases (Yearly) stood at $605,000 in 2021, then skyrocketed by 174.55% to $1.7 million in 2022, then dropped by 23.72% to $1.3 million in 2023, then tumbled by 55.41% to $565,000 in 2024.